Inhibition of mTOR suppresses experimental liver tumours

Anticancer Research

Volumn 25, Issue 2 A, 2005, Pages 789-793

  Rizell, Magnus ^a   Lindner, Per ^a  

^a SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Adenocarcinoma; Hepatoma; Liver; Rat; Sarcoma; Sirolimus

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; NITROSOGUANIDINE; PROTEIN KINASE INHIBITOR; RAPAMYCIN; UNCLASSIFIED DRUG;

ADENOCARCINOMA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; ENZYME MECHANISM; FOOD INTAKE; IN VIVO STUDY; LEYDIG CELL; LIVER CARCINOMA; LIVER CELL CARCINOMA; LIVER TUMOR; LIVER WEIGHT; NONHUMAN; PRIORITY JOURNAL; RAT; REGULATORY MECHANISM; SARCOMA; SPLEEN WEIGHT; TUMOR VOLUME;

ADENOCARCINOMA; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; COLONIC NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; EATING; LEYDIG CELL TUMOR; LIVER; LIVER NEOPLASMS, EXPERIMENTAL; ORGAN SIZE; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; RATS; RATS, INBRED WF; SIROLIMUS; SPLEEN;

EID: 17444426124     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Heitman J, Movva NR and Hall MN: Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 253: 905-909, 1991.
2. Fingar DC and Blenis J: Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression. Oncogene 23: 3151-3171, 2004.
3. Sawyers CL: Opportunities and challenges in the development of kinase inhibitor therapy for cancer. Genes Dev 17: 2998-3010, 2003.
4. Neshat MS, Mellinghoff IK, Tran C, Stiles B, Thomas G, Petersen R, Frost P, Gibbons JJ, Wu H and Sawyers CL: Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA 98: 10314-10319, 2001.
5. Douros J and Suffness M: New antitumor substances of natural origin. Cancer Treat Rev 8: 63-87, 1981.
6. Guba M, von Breitenbuch P, Steinbauer M, Koehl G, Flegel S, Hornung M, Bruns CJ, Zuelke C, Farkas S, Anthuber M, Jauch KW and Geissler EK: Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 8: 128-135, 2002.
7. Rizell M: Histamine Treatment of Malignant Tumour. Sahlgrenska Academy, Department of Sugery. Göteborg: University of Göteborg, 2003.
8. Mordes JP and Rossini AA: Tumour-induced anorexia in the Wistar rat. Science 213: 565-567, 1981.
9. Steele G Jr and Sjogren HO: Cross-reacting tumour-associated antigen (s) among chemically induced rat colon carcinomas. Cancer Res 34: 1801-1807, 1974.
10. Boffa DJ, Luan F, Thomas D, Yang H, Sharma VK, Lagman M and Suthanthiran M: Rapamycin inhibits the growth and metastatic progression of non-small cell lung cancer. Clin Cancer Res 10: 293-300, 2004.
11. Lindner P, Heath DD, Shalinsky DR, Howell SB, Naredi P and Hafstrom L: Regional lymphatic drug exposure following intraperitoneal administration of 5-fluorouracil, carboplatin, and etoposide. Surg Oncol 2: 105-112, 1993.
12. Choe G, Horvath S, Cloughesy TF, Crosby K, Seligson D, Palotie A, Inge L, Smith BL, Sawyers CL and Mischel PS: Analysis of the phosphatidylinositol 3′-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res 63: 2742-2746, 2003.
13. Thevananther S, Sun H, Li D, Arjunan V, Awad SS, Wyllie S, Zimmerman TL, Goss JA and Karpen SJ: Extracellular ATP activates c-jun N-terminal kinase signaling and cell cycle progression in hepatocytes. Hepatology 39: 393-402, 2004.
14. Shamji AF, Nghiem P and Schreiber SL: Integration of growth factor and nutrient signaling: implications for cancer biology. Mol Cell 12: 271-280, 2003.
15. Kim DH, Sarbassov DD, Ali SM, King JE, Latek RR, Erdjument-Bromage H, Tempst P and Sabatini DM: mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110: 163-175, 2002.
16. Panwalkar A, Verstovsek S and Giles FJ: Mammalian target of rapamycin inhibition as therapy for hematologic malignancies. Cancer 100: 657-666, 2004.
17. Huang S, Shu L, Dilling MB, Easton J, Harwood FC, Ichijo H and Houghton PJ: Sustained activation of the JNK cascade and rapamycin-induced apoptosis are suppressed by p53/p21(Cip1). Mol Cell 11: 1491-1501, 2003.
18. Wendel HG, De Stanchina E, Fridman JS, Malina A, Ray S, Kogan S, Cordon-Cardo C, Pelletier J and Lowe SW: Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 428: 332-337, 2004.
19. Hudson CC, Liu M, Chiang GG, Otterness DM, Loomis DC, Kaper F, Giaccia AJ and Abraham RT: Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 22: 7004-7014, 2002.
20. Zhang D and Brodt P: Type 1 insulin-like growth factor regulates MT1-MMP synthesis and tumor invasion via PI 3-kinase/Akt signaling. Oncogene 22: 974-982, 2003.
21. Attur MG, Patel R, Thakker G, Vyas P, Levartovsky D, Patel P, Naqvi S, Raza R, Patel K, Abramson D, Bruno G, Abramson SB and Amin AR: Differential anti-inflammatory effects of immunosuppressive drugs: cyclosporin, rapamycin and FK-506 on inducible nitric oxide synthase, nitric oxide, cyclooxygenase-2 and PGE2 production. Inflamm Res 49: 20-26, 2000.
22. Tunon MJ, Sanchez-Campos S, Gutierrez B, Culebras B, Gonzalez-Gallego J: Effects of FK506 and rapamycin on generation of reactive oxygen species, nitric oxide production and nuclear factor kappa B activation in rat hepatocytes. Biochem Pharmacol 66(3): 439-45, 2003.
23. Bruns CJ, Koehl GE, Guba M, Yezhelyev M, Steinbauer M, Seeliger H, Schwend A, Hoehn A, Jauch KW and Geissler EK: Rapamycin-induced endothelial cell death and tumor vessel thrombosis potentiate cytotoxic therapy against pancreatic cancer. Clin Cancer Res 10: 2109-2119, 2004.
24. Seeliger H, Guba M, Koehl GE, Doenecke A, Steinbauer M, Bruns CJ, Wagner C, Frank E, Jauch KW and Geissler EK: Blockage of 2-deoxy-D-ribose-induced angiogenesis with rapamycin counteracts a thymidine phosphorylase-based escape mechanism available for colon cancer under 5-fluorouracil therapy. Clin Cancer Res 10: 1843-1852, 2004.